Pralsetinib (Gavreto)

Do Not Prescribe (DNP)
Decision Date:
September 2022


DNP: NICE TA812 Pralsetinib for treating RET fusion-positive advanced non-small-cell lung cancer. NHSE commissioned. 

Do Not Prescribe (DNP) Drug Classifications

  • 2: Have a lack of data on safety compared with standard therapy
  • 4: Have a lack of data on cost-effectiveness compared with standard therapy

search again

Derby and Derbyshire ICB

Derby and Derbyshire ICB

Please click the button to navigate to our app

Redirect to app